BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Elritercept readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Elritercept\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05037760-11364@assetmemo.bio
DTSTAMP:20261121T005603Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Elritercept: Phase 2 readout est. (NCT05037760)
DESCRIPTION:Elritercept\, phase 2.\nStudy: A Study of Elritercept Alone or 
 Together With Ruxolitinib in Adults With Myelofibrosis\nEstimated primary 
 completion: 28 February 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/elritercept#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05037760
URL:https://assetmemo.bio/drug/elritercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07319845-11364@assetmemo.bio
DTSTAMP:20261121T005603Z
DTSTART;VALUE=DATE:20280626
DTEND;VALUE=DATE:20280627
SUMMARY:Elritercept: Phase 2 readout est. (NCT07319845)
DESCRIPTION:Elritercept\, phase 2\, Myelodysplastic Syndromes.\nStudy: A St
 udy of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodyspla
 stic Syndromes\nEstimated primary completion: 26 June 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/elritercept#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07319845
URL:https://assetmemo.bio/drug/elritercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06499285-11364@assetmemo.bio
DTSTAMP:20261121T005603Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Elritercept: Phase 3 readout est. (NCT06499285)
DESCRIPTION:Elritercept\, phase 3\, Myelodysplastic Syndromes.\nStudy: A St
 udy of Elritercept to Treat Anemia in Adults With Very Low\, Low\, or Inte
 rmediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Trans
 fusions\nEstimated primary completion: 15 September 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/elritercept#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06499285
URL:https://assetmemo.bio/drug/elritercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07422480-11364@assetmemo.bio
DTSTAMP:20261121T005603Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Elritercept: Phase 3 readout est. (NCT07422480)
DESCRIPTION:Elritercept\, phase 3\, Myelodysplastic Syndromes.\nStudy: A St
 udy to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults Wit
 h Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Tra
 nsfusions\nEstimated primary completion: 30 April 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/elritercept#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07422480
URL:https://assetmemo.bio/drug/elritercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04419649-11364@assetmemo.bio
DTSTAMP:20261121T005603Z
DTSTART;VALUE=DATE:20291030
DTEND;VALUE=DATE:20291031
SUMMARY:Elritercept: Phase 2 readout est. (NCT04419649)
DESCRIPTION:Elritercept\, phase 2\, Myelodysplastic Syndromes.\nStudy: A St
 udy of Elritercept to Treat Anemia in Adults With Very Low\, Low\, or Inte
 rmediate Risk Myelodysplastic Syndromes (MDS)\nEstimated primary completio
 n: 30 October 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 lritercept#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT04419649
URL:https://assetmemo.bio/drug/elritercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623161-11364@assetmemo.bio
DTSTAMP:20261121T005603Z
DTSTART;VALUE=DATE:20291207
DTEND;VALUE=DATE:20291208
SUMMARY:Elritercept: Phase 3 readout est. (NCT07623161)
DESCRIPTION:Elritercept\, phase 3.\nStudy: A Study to Compare Elritercept t
 o Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitin
 ib\nEstimated primary completion: 7 December 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/elritercept#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07623161
URL:https://assetmemo.bio/drug/elritercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
